Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells $125,000.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) insider Adam Crystal sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the transaction, the insider owned 115,743 shares of the company’s stock, valued at $2,893,575. This trade represents a 4.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Adam Crystal also recently made the following trade(s):

  • On Monday, November 2nd, Adam Crystal sold 5,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $22.42, for a total transaction of $112,100.00.
  • On Thursday, October 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $24.47, for a total value of $660,690.00.

Tango Therapeutics Price Performance

Shares of TNGX stock opened at $25.50 on Monday. Tango Therapeutics, Inc. has a 52 week low of $7.60 and a 52 week high of $34.39. The firm has a 50 day moving average of $23.53 and a 200-day moving average of $22.79. The company has a market cap of $4.32 billion, a price-to-earnings ratio of -18.61 and a beta of 1.26.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). Analysts anticipate that Tango Therapeutics, Inc. will post -1.46 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TNGX. Allspring Global Investments Holdings LLC lifted its stake in shares of Tango Therapeutics by 4.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 13,734 shares of the company’s stock worth $336,000 after buying an additional 534 shares in the last quarter. Allworth Financial LP lifted its position in Tango Therapeutics by 100.9% in the 2nd quarter. Allworth Financial LP now owns 1,131 shares of the company’s stock valued at $35,000 after acquiring an additional 568 shares in the last quarter. Nykredit A S purchased a new stake in Tango Therapeutics during the 2nd quarter valued at $26,000. Bleakley Financial Group LLC raised its stake in shares of Tango Therapeutics by 7.0% in the third quarter. Bleakley Financial Group LLC now owns 13,162 shares of the company’s stock worth $328,000 after purchasing an additional 860 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Tango Therapeutics by 0.5% during the first quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company’s stock valued at $10,237,000 after purchasing an additional 2,272 shares in the last quarter. 78.99% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TNGX has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their target price on shares of Tango Therapeutics from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 10th. Stifel Nicolaus set a $55.00 price target on shares of Tango Therapeutics in a research report on Friday, October 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tango Therapeutics in a research note on Wednesday, November 4th. Guggenheim upped their target price on Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Wedbush cut their price objective on Tango Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 10th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.54.

Get Our Latest Analysis on Tango Therapeutics

Top Tango Therapeutics Stories

Here are a few of the latest stories about TNGX:

  • Positive Sentiment: Canaccord Genuity reaffirmed its Buy rating, while HC Wainwright also maintained a Buy rating and a $67 price target despite revising its forecasts. Continued Buy ratings may help offset concerns about near-term losses. Canaccord Genuity sticks to its Buy rating HC Wainwright lowers expectations
  • Neutral Sentiment: Shares moved above their 50-day moving average despite the earnings miss, a technical signal that may indicate improving near-term momentum. TNGX moves above its 50-day moving average
  • Negative Sentiment: Tango reported a quarterly loss of $0.39 per share, wider than the $0.35 loss analysts expected, underscoring continued operating losses.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.

Featured Articles

Insider Buying and Selling by Quarter for Tango Therapeutics (NASDAQ:TNGX)

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.